SSc that occurs in the lungs is called SSc-ILD. It is estimated that approximately 100,000 people in the U.S. are affected by SSc and up to 80% may develop ILD.

Proton pump inhibitors with histamine 2 receptor antagonists reduced all-cause mortality in patients with SSc-ILD. Combination therapy outperformed single-agent treatment for improved survival.

PH-ILD is an underserved severe disease. Approximately 30% of ILD patients develop PH, with up to 100,000 diagnosed PH-ILD patients in the U.S. 1 ...

At 52 weeks, 20.6% of the upadacitinib group and 37.5% of the mycophenolate group had ≥ 5% absolute decline from baseline in FVC. A 10% drop in FVC from baseline at 1 year was also more common ...

Despite patients sharing a usual interstitial pneumonia (UIP) pattern on lung CT scans, patients with connective tissue disease-related interstitial lung disease (CTD-ILD) demonstrated a slower ...